Recent Advances in Liquid Biopsy of Brain Cancers
Brain cancers are among the top causes of death worldwide. Although, the survival rates vary widely depending on the type of the tumor, early diagnosis could generally benefit in better prognosis outcomes of the brain cancer patients. Conventionally, neuroimaging and biopsy are the most widely used...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-09-01
|
Series: | Frontiers in Genetics |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fgene.2021.720270/full |
id |
doaj-204fca66fc1c4f589002fc76fc00661c |
---|---|
record_format |
Article |
spelling |
doaj-204fca66fc1c4f589002fc76fc00661c2021-09-17T05:25:48ZengFrontiers Media S.A.Frontiers in Genetics1664-80212021-09-011210.3389/fgene.2021.720270720270Recent Advances in Liquid Biopsy of Brain CancersYunyun An0Fei Fan1Xiaobing Jiang2Kun Sun3Kun Sun4Shenzhen Bay Laboratory, Shenzhen, ChinaDepartment of Neurosurgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaDepartment of Neurosurgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaShenzhen Bay Laboratory, Shenzhen, ChinaBGI-Shenzhen, Shenzhen, ChinaBrain cancers are among the top causes of death worldwide. Although, the survival rates vary widely depending on the type of the tumor, early diagnosis could generally benefit in better prognosis outcomes of the brain cancer patients. Conventionally, neuroimaging and biopsy are the most widely used approaches in diagnosis, subtyping, and prognosis monitoring of brain cancers, while emerging liquid biopsy assays using peripheral blood or cerebrospinal fluid have demonstrated many favorable characteristics in this task, especially due to their minimally invasive and easiness in sampling nature. Here, we review the recent studies in the liquid biopsy of brain cancers. We discuss the methodologies and performances of various assays on diagnosis, tumor subtyping, relapse prediction as well as prognosis monitoring in brain cancers, which approaches have made a big step toward clinical benefits of brain cancer patients.https://www.frontiersin.org/articles/10.3389/fgene.2021.720270/fullperipheral bloodcerebrospinal fluidcell-free DNAnoninvasivecancer diagnosis |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Yunyun An Fei Fan Xiaobing Jiang Kun Sun Kun Sun |
spellingShingle |
Yunyun An Fei Fan Xiaobing Jiang Kun Sun Kun Sun Recent Advances in Liquid Biopsy of Brain Cancers Frontiers in Genetics peripheral blood cerebrospinal fluid cell-free DNA noninvasive cancer diagnosis |
author_facet |
Yunyun An Fei Fan Xiaobing Jiang Kun Sun Kun Sun |
author_sort |
Yunyun An |
title |
Recent Advances in Liquid Biopsy of Brain Cancers |
title_short |
Recent Advances in Liquid Biopsy of Brain Cancers |
title_full |
Recent Advances in Liquid Biopsy of Brain Cancers |
title_fullStr |
Recent Advances in Liquid Biopsy of Brain Cancers |
title_full_unstemmed |
Recent Advances in Liquid Biopsy of Brain Cancers |
title_sort |
recent advances in liquid biopsy of brain cancers |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Genetics |
issn |
1664-8021 |
publishDate |
2021-09-01 |
description |
Brain cancers are among the top causes of death worldwide. Although, the survival rates vary widely depending on the type of the tumor, early diagnosis could generally benefit in better prognosis outcomes of the brain cancer patients. Conventionally, neuroimaging and biopsy are the most widely used approaches in diagnosis, subtyping, and prognosis monitoring of brain cancers, while emerging liquid biopsy assays using peripheral blood or cerebrospinal fluid have demonstrated many favorable characteristics in this task, especially due to their minimally invasive and easiness in sampling nature. Here, we review the recent studies in the liquid biopsy of brain cancers. We discuss the methodologies and performances of various assays on diagnosis, tumor subtyping, relapse prediction as well as prognosis monitoring in brain cancers, which approaches have made a big step toward clinical benefits of brain cancer patients. |
topic |
peripheral blood cerebrospinal fluid cell-free DNA noninvasive cancer diagnosis |
url |
https://www.frontiersin.org/articles/10.3389/fgene.2021.720270/full |
work_keys_str_mv |
AT yunyunan recentadvancesinliquidbiopsyofbraincancers AT feifan recentadvancesinliquidbiopsyofbraincancers AT xiaobingjiang recentadvancesinliquidbiopsyofbraincancers AT kunsun recentadvancesinliquidbiopsyofbraincancers AT kunsun recentadvancesinliquidbiopsyofbraincancers |
_version_ |
1717377545620422656 |